A randomized, double‐blind, placebo‐controlled, dose‐finding trial with Lolium perenne peptide immunotherapy

BACKGROUND: A novel subcutaneous allergen immunotherapy formulation (gpASIT+™) containing Lolium perenne peptides (LPP) and having a short up‐dosing phase has been developed to treat grass pollen–induced seasonal allergic rhinoconjunctivitis. We investigated peptide immunotherapy containing the hydr...

Descripción completa

Detalles Bibliográficos
Autores principales: Mösges, R., Kasche, E. M., Raskopf, E., Singh, J., Sohlich, L., Astvatsatourov, A., Shah‐Hosseini, K., Pirotton, S., Haazen, L., Durham, S. R., Legon, T., Zadoyan, G., Shamji, M. H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5947135/
https://www.ncbi.nlm.nih.gov/pubmed/29150857
http://dx.doi.org/10.1111/all.13358

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5947135/
https://www.ncbi.nlm.nih.gov/pubmed/29150857
http://dx.doi.org/10.1111/all.13358

Ejemplares similares